Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations

16 Oct 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31628917
DOI: 10.1016/j.taap.2019.114771

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitationsPMID 31628917Read ↗

Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVIDSemantic proximity Read ↗

Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directionsSemantic proximity Read ↗

Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trialsSemantic proximity Read ↗

Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncologySemantic proximity Read ↗

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read ↗

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future PerspectivesSemantic proximity Read ↗

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Will kinase inhibitors have a dark side?Semantic proximity Read ↗

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read ↗

Kinase-targeted cancer therapies: progress, challenges and future directionsSemantic proximity Read ↗

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.Semantic proximity Read ↗

Evolution of PIKK family kinase inhibitors A new age cancer therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.